Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 17, Number 3—March 2011

Research

Targeted Drug-Resistance Testing Strategy for Multidrug-Resistant Tuberculosis Detection, Lima, Peru, 2005–2008

Gustavo E. Velásquez, Martin Yagui, J. Peter Cegielski, Luis Asencios, Jaime Bayona, Cesar Bonilla, Hector O. Jave, Gloria Yale, Carmen Suárez, Sidney Atwood, Carmen C. Contreras, and Sonya S. ShinComments to Author 
Author affiliations: Author affiliations: Brigham and Women’s Hospital, Boston, Massachusetts, USA (G.E. Velásquez, S. Atwood, S.S. Shin); Instituto Nacional de Salud, Lima, Peru (M. Yagui, L. Asencios); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (J.P. Cegielski); Socios En Salud, Lima (J. Bayona, C.C. Conteras, S.S. Shin); Partners In Health, Boston (S.S. Shin); Dartmouth College, Hanover, New Hampshire, USA (J. Bayona); Ministerio de Salud del Perú, Lima (C. Bonilla, H.O. Jave); Dirección de Salud V Lima Ciudad, Lima (G. Yale); Dirección de Salud IV Lima Este, Lima (C. Suárez)

Main Article

Table 4

MDR TB among new smear-positive TB patients compared with regional surveillance prevalence estimates, by NTP risk group, Lima, Peru, 2005–2008*

Risk factor Total no. patients No. (%)
MDR TB Odds ratio (95% CI)
New smear-positive TB patients in NTP regional surveillance data 476 47 (9.9)
New smear-positive TB patients in study cohort 531 180 (33.9) 4.68 (3.30–6.65)
HIV positive 46 8 (17.4) 1.92 (0.85– 4.36)
Diabetes mellitus 107 18 (16.8) 1.85 (1.02–3.33)
Chronic corticosteroid therapy 4 0 NA
Other immunosuppression 5 0 NA
Adverse reaction 4 1 (25.0) 3.04 (0.06–38.63)
Previous hospitalization within the past 2 y with duration >15 d 5 2 (40.0) 6.09 (0.49–54.15)
Health care worker during the past 2 y 24 4 (16.7) 1.83 (0.60–5.57)
Health sciences student during the past 2 y 29 5 (17.2) 1.90 (0.69–5.22)
Prisoner during the past 2 y 27 4 (14.8) 1.59 (0.53–4.79)
Adult patient with household contact risk factor(s)† 170 57 (33.5) 4.60 (2.97–7.14)
Pediatric patient with household contact risk factor(s)† 13 7 (53.9) 10.65 (2.90–39.71)
Private or self-administered treatment 2 2 (100.0) NA
Sputum positive during second or third month of category I treatment 105 70 (66.7) 18.26 (11.01–30.26)
Sputum positive during second or third month of category II treatment 1 1 (100.0) NA

*MDR, multidrug resistant; TB, tuberculosis; NTP, National Tuberculosis Control Program; CI, confidence interval; NA, not applicable.
†Household contact risk factors are defined as household contact with a patient with known MDR TB, with a patient who showed TB treatment failure in the past 2 y, or with a patient being treated with second-line TB drugs.

Main Article

TOP